Bodycote plc (LSE:BOY), the heat treatment and specialist thermal processing group, has agreed a recommended cash Takeover backed by Veritas Capital. Under a firm offer announced on 1 September 2026, Vulcan Alpha Bidco Limited, a company indirectly wholly owned by funds managed or controlled by Veritas Capital Fund Management, L.L.C., would acquire Bodycote for an Offer Value of 940p per share.

That value comprises 932.8p in cash plus the 7.2p Interim Dividend for the 2026 financial year, which shareholders can keep without any reduction to the offer. The deal is being implemented through a scheme of arrangement under Part 26 of the Companies Act, and if it completes, Bodycote would leave the London market and the FTSE 250.

The situation is not entirely settled. On the same day, CVC Advisers Limited said it had noted the Veritas firm offer, was considering its position, and advised Bodycote shareholders to take no action on the Veritas offer in the meantime. CVC's statement is a possible offer only, and there is no certainty that any CVC offer will be made.

The Terms: What Veritas Is Offering

The cash element of 932.8p represents a premium of about 36.5% to Bodycote's three-month volume-weighted average price (VWAP) of 683.4p up to 21 May 2026, the undisturbed reference date. It is a premium of about 41.4% to the 12-month VWAP of 659.5p.

Measured against other reference points, the cash price is 44.0% above the 647.8p closing price on 7 July 2026, before Veritas made its initial proposal, and 24.3% above the 750.2p close on 4 August 2026, the day before the current Offer Period began. The narrower final figure reflects the extent to which the shares had already moved as bid interest built.

Because the offer is structured as a scheme of arrangement, it will require approval from shareholders at court and general meetings, followed by sanction from the court. Once effective, a scheme binds all shareholders. The detailed timetable and conditions have not been reviewed for this article, so no expected completion date is given here.

A Contested Route to a Firm Offer

The Veritas deal follows months of bid activity. On 22 May 2026, Bodycote confirmed it had received a possible offer approach after press speculation. On 5 June, Apollo Management X said it did not intend to make a firm offer, and Bodycote's board responded by expressing strong confidence in its standalone strategy, known as Optimise, Perform and Grow. That ended the first offer period.

Interest then returned. On 5 August, the board confirmed it had received two separate conditional proposals. One came from CVC at up to 915p per share, made up of 907.8p in cash and the 7.2p dividend, which the board said it was minded to recommend if a firm offer were made at that level. Details of the second proposal have not been reviewed for this article.

The firm offer from Veritas on 1 September came in at 940p, higher than the CVC proposal. With the board recommending Veritas' terms and CVC publicly weighing its options, the process has moved from a possible-offer phase to a firm recommended bid that shareholders will be asked to vote on.

The Business Being Acquired

Bodycote provides heat treatment and specialist thermal processing services, which improve the properties of metal components such as strength, hardness and resistance to wear or corrosion. Its operations are organised into Specialist Technologies and Precision Heat Treatment, and the group is led by chief executive Jim Fairbairn.

The company's interim results, published on 28 July 2026, showed first-half trading in line with expectations and an unchanged full-year outlook. Group Revenue rose 3.3% to £381.2m, with organic growth of 6.5%. Core revenue was £372.0m, up 9.6% on an organic basis. Adjusted operating profit increased 10.7% to £61.0m, lifting the Margin by 110 basis points to 16.0%, while statutory operating profit also rose 10.7% to £45.6m.

Adjusted Basic Earnings Per Share grew 18.3% to 25.2p, and statutory EPS was 18.1p. The interim dividend was raised 4.3% to 7.2p, the same payment that sits within the Offer Value. Bodycote (LSE:BOY) also spent £12.6m in the half under its £80m buyback programme, repurchasing 1.9 million shares.

Growth Markets and the Automotive Drag

The first half highlighted a clear split in Bodycote's end markets. The company reported strong growth in its target sectors of aerospace and defence, industrial gas turbines, medical and semiconductors. Specialist Technologies, which serves many of these higher-value markets, grew organically by 16.7%, while Precision Heat Treatment achieved organic growth of 6.4%.

Automotive remained weak, particularly in Europe, where Bodycote described structural weakness in the Western European market. The Optimise programme, which targets non-core sites, was said to be on track, and the company was exploring extending it to more sites exposed to challenging automotive and industrial markets. Management said it remained confident in its mid-term targets.

Risks and Uncertainties for Shareholders

The main risk is completion. Schemes of arrangement depend on Shareholder votes, court sanction and any regulatory or other conditions, and deals can be delayed or fail. If the Veritas offer lapsed, Bodycote's shares would once again be valued on standalone prospects.

CVC's statement adds uncertainty. It has not made an offer, and there is no certainty that it will. Shareholders face a decision on the recommended Veritas terms while that position remains open, and this article does not speculate on whether any rival offer will emerge.

For the underlying business, the risks include continued weakness in European automotive Demand and the execution of the Optimise programme. Those matter most if the deal does not proceed, as they would shape Bodycote's performance as an independent listed company.

What to Watch Next

The key items to monitor are publication of the scheme document, the dates of the court and general meetings, and the outcome of the shareholder votes. Any further statement from CVC, whether confirming or ruling out an offer, will also be significant.

Investors will also watch for progress on regulatory clearances and the court hearing needed to make the scheme effective. Until the scheme becomes effective, Bodycote remains a FTSE 250 constituent.

Conclusion

Veritas' 940p recommended cash offer represents a significant premium to Bodycote's undisturbed share price and, if completed, would take the company out of the FTSE 250 and off the London market. The board has backed the terms, while CVC has said only that it is considering its position. For shareholders, the coming scheme process and any further developments in the offer period will determine how this story concludes.